文献速递妇科

卵巢癌肿瘤细胞减灭术中结直肠切除吻合后转流性回肠造口的指征与实践

Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.
PubMed 文献 · Gynecol Oncol · 2020-06-19

这项回顾性多中心研究纳入695例接受原发性结直肠吻合的卵巢癌手术患者,转流性回肠造口率为19.13%(133/695),各中心范围4.6-24.32%。既往贝伐珠单抗治疗、额外肠切除、手术时间延长和术中红细胞输血与造口实施独立相关。作者认为驱动造口决策的风险因素似乎不同于实际与吻合口漏相关的因素。

要点

  • 转流性回肠造口率为19.13%(133/695),各中心范围4.6-24.32%。
  • 既往贝伐珠单抗治疗(OR 2.8)、额外肠切除(OR 3.0)、手术时间延长(OR 1.005)和术中红细胞输血(OR 2.7)与造口实施独立相关。
  • 以7%吻合口漏率为界值时,高达51.8%的转流性回肠造口者吻合口漏风险低于7%,可能得以避免造口。

核心结论

  • 驱动妇科肿瘤外科医生实施转流性回肠造口的风险因素,似乎不同于作者已识别的与实际术后吻合口漏相关的风险因素。
  • 更广泛地认识导致较高围手术期风险的风险因素,将有助于更好的风险分层,并可能避免卵巢癌患者不必要的造口形成。

研究设计与样本

  • 回顾性研究,8家医院参与。
  • 纳入2010年1月至2018年6月因卵巢癌接受原发性结直肠吻合手术的695例患者。
  • 识别并分析14个术前/术中定义的变量作为实施转流性回肠造口的依据因素。

主要发现

  • 整个队列转流性回肠造口率为19.13%(133/695;各中心内范围4.6-24.32%)。
  • 既往贝伐珠单抗治疗与转流性回肠造口实施独立相关(OR 2.8,95%CI 1.3-6.1;p=0.01)。
  • 额外肠切除与转流性回肠造口实施独立相关(OR 3.0,95%CI 1.8-5.1;p<0.001)。
  • 手术时间延长与转流性回肠造口实施独立相关(OR 1.005,95%CI 1.003-1.006;p<0.001)。
  • 术中红细胞输血与转流性回肠造口实施独立相关(OR 2.7,95%CI 1.4-5.3;p<0.001)。

临床怎么用

  • 作者认为,更广泛地认识导致较高围手术期风险的风险因素,将有助于更好的风险分层,并可能避免卵巢癌患者不必要的造口形成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the factors related with diverting ileostomy performance after colorectal resection and anastomosis, in advanced ovarian cancer cytoreductive surgery. METHODS: We have previously demonstrated the risk factors associated with anastomotic leak after colorectal anastomosis: Advanced age at surgery, low serum albumin level, additional bowel resections, manual anastomosis and distance of the anastomosis from the anal verge. However, use of diverting ileostomy is strongly variable and depends on individual surgeon preferences and training. Eight hospitals participated in this retrospective study. Data of 695 patients operated for ovarian cancer with primary colorectal anastomosis were included (January 2010-June 2018). Fourteen pre-/intraoperatively defined variables were identified and analysed as justification factors for use of diverting ileostomy. RESULTS: The rate of diverting ileostomy in the entire cohort was 19.13% (133/695; range within individual centers 4.6-24.32%). Previous treatment with bevacizumab [OR 2.8 (1.3-6.1); p=0.01]; additional bowel resections [OR 3.0 (1.8-5.1); p<0.001]; extended operating time [OR 1.005 (1.003-1.006); p<0.001] and intra-operative red blood transfusion [OR 2.7 (1.4-5.3); p<0.001] were found to be independently associated with diverting ileostomy performance. Assuming a 7% AL rate cut-off, up to 51.8% of DI presented an AL risk below 7% and might have been spared. CONCLUSIONS: The risk factors that drive the gynecologic oncology surgeons to perform a diverting ileostomy, seem to differ from the actual risk factors that we have identified to be associated with postoperative anastomotic leak. Broader awareness of the risk factors that contribute to a higher perioperative risk profile, will facilitate a better risk stratification process and possibly avoid unnecessary stoma formation in ovarian cancer patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lago V, Fotopoulou C, Chiantera V, et al. Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction. Gynecol Oncol. 2020. PMID: 32571682. doi:10.1016/j.ygyno.2020.05.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。